Traws Pharma Inc
$ 1.59
-1.24%
14 Apr - close price
- Market Cap 12,865,300 USD
- Current Price $ 1.59
- High / Low $ 1.67 / 1.55
- Stock P/E N/A
- Book Value 0.64
- EPS -1.82
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.92 %
- ROE -10.60 %
- 52 Week High 3.27
- 52 Week Low 0.97
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Analyst Target Price
$7.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-15 | 2024-05-15 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-15 | 2023-03-16 |
| Reported EPS | -0.34 | -0.16 | 22.4413 | 26.6 | -8.81 | -4.8652 | -0.19 | -0.19 | -0.23 | -0.2 | -0.28 | -0.26 |
| Estimated EPS | -9.16 | -8.75 | -0.265 | -0.25 | -6.25 | -6.25 | -0.23 | -0.25 | -0.29 | -0.31 | -0.3 | -0.26 |
| Surprise | 8.82 | 8.59 | 22.7063 | 26.85 | -2.56 | 1.3848 | 0.04 | 0.06 | 0.06 | 0.11 | 0.02 | 0 |
| Surprise Percentage | 96.2882% | 98.1714% | 8568.4151% | 10740% | -40.96% | 22.1568% | 17.3913% | 24% | 20.6897% | 35.4839% | 6.6667% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRAW
2026-04-15 21:10:13
Traws Pharma announced its 2025 financial results, highlighting significant progress in its influenza (TXM) and COVID-19 (ratutrelvir) programs, including positive Phase 2a data for ratutrelvir. The company secured a $60 million PIPE financing, extending its cash runway into Q1 2027 to advance these clinical programs and pursue regulatory approvals. Leadership appointments and a "Buy" analyst rating with a $6.50 price target also support the company's strategic direction, though weak financial performance poses a funding risk.
2026-04-15 20:10:13
Traws Pharma reported its full-year 2025 financial results and business highlights, focusing on the advancement of its lead investigational program, tivoxavir marboxil (TXM), for influenza prophylaxis and treatment. The company also announced the completion of a private financing round raising up to $60 million, which is expected to fund operations into Q1 2027. Key developments include progress on the TXM human influenza challenge trial, positive Phase 2a results for ratutrelvir in COVID patients, and a significant reduction in net loss compared to the previous year.
2026-04-15 20:10:13
Traws Pharma reported a significant turnaround in 2025, moving from a $166.5 million net loss in 2024 to a $9.2 million net income, primarily due to lower R&D charges and a favorable debt valuation. The company also secured a private investment in public equity (PIPE) of up to $60 million, including an initial $10 million, which is expected to fund operations into Q1 2027. This funding will support continued development of its influenza therapeutic, tivoxavir marboxil, and further analysis of its COVID-19 drug, ratutrelvir, which showed positive Phase 2a results.
2026-04-15 16:10:13
Traws Pharma, Inc. has secured approximately $10 million in funding by closing a securities purchase agreement. The agreement involves issuing common shares and various series of warrants, with the potential for additional aggregate gross proceeds of about $30 million if fully exercised. The private placement is anticipated to finalize around April 16, 2026.
2026-04-15 12:10:13
Traws Pharma (NASDAQ: TRAW) has secured an upfront cash infusion of $10 million through a private placement (PIPE) financing, with the potential to raise up to an additional $50 million via milestone-based and three-year warrants, totaling $60 million. The primary goal of this financing is to fund a human challenge trial in the UK for its influenza drug candidate, tivoxavir marboxil, pending MHRA approval. The deal, priced at $1.6730 per share, aims to advance Traws Pharma's respiratory viral disease pipeline while providing access to further capital upon achieving key development milestones, though potential dilution for existing shareholders is noted.
2026-04-14 06:39:52
hVIVO has secured a contract with Traws Pharma to conduct a Phase 2a human challenge trial for its antiviral candidate, tivoxavir marboxil, against influenza. The trial will assess the safety and efficacy of the single-dose oral treatment in about 150 healthy participants at hVIVO's facilities. This agreement highlights the demand for hVIVO's integrated human challenge model, with revenue expected primarily in 2026.
